Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Recent hire with a Nestle connection and has developed products for Asia. Interesting as we are doing really well in Asia and partnered with Nestle.
Jmho
Wow, quite a historical piece of DD. I don't think they are working any longer with P&G. Would be nice, but pretty sure they are out of the picture. Let me know if you've heard differently.
P&G?
Nestle is still wrestling with solubility issues (for nutrition drinks). If they ever figure that out, then we are moving forward in a significant way. Until then, its a slog.
Great points JfK. Their normal model does seem to target a different consumer. Their must be value for the customer and a profit in their models to give up shelf space. I will have to look into their 2 different price point products they are selling.
Also P&G and Nestle are signed on, seems like this is going to “blanket” saturate the market pretty soon and in doing so must have good solid data to do so. Profits should follow.
3 billionaires and 3 major Brands pursuing Tru Niagen.......it must have passed the smell test!
I have to believe that WalMart is only taking this because they were advised there are some major studies with expected quite positive results that can be leveraged 2H21, and/or they plan on making a major strategic push to put money and marketing knowhow behind healthy supplementation of diet and lifestyle....as part of 'up-scaling' their customer base. Otherwise, this doesn't make sense. TruNiagen does not currently fit with their customer base, and the TruNiagen target market would not be aware of TruNiagen being stocked in a WalMart type retailer. I do curbside pickup from WMT each week, and as a regular customer they are not soliciting me with ads of any kind. Something doesn't seem right, and I hope that WMT has very good reasons to bring this item in.
Some nice attempts to stea...grab some shares these days. 3,000 walmart stores is a nice chunk of change with not one but two price points? Must be, buy 3 and watch out for the “falling prices”. Walmart doesnt normally let just any product on their shelf. If not a takeover target before Q3 or more importantly Q4, we should have some impressive revenue ramp up.
Congrats. I should have sold more of my shares when I could early on. Plan to buy back the shares I did sell.
A tidy profit of around 400% of invested price if they have been selling into this volume.
I guess I missed my prediction on the top today but it did hit $22 pre-market. I closed my short at $18 - could have gotten another $4 out of it I see now. didn't think it would drop this fast today.
13G filing, which I think relates to the earlier $25MM stock placement:
http://archive.fast-edgar.com/20210226/AWZGJ22CW222R2C2222M22Z2FSTRZ22I9232
I think it will hit yesterday’s AH high just under 25 and then settle down
I might scalp a small short at 23 but will watch.
Bull, what price levels does your model show?
The price and volume action looks very much like a high volume trap here. Fund the company, convert the shares, sell into Hugh volume spike.
I’d look to see this possibly run at the high one more time today and then start to
Drop back toward 10.
I believe I read some time back Proctor and
Gamble is partnered as well for a line of products.
Would not be surprised by a buyout. They already have a commercial relationship with nestle for adding NR to nestle products. Time will tell. No rush on my part.
Then I'm also sure you noticed the amended form 4s issued at the beginning of November of last year? If you haven't take a look at the date the options are exercisable, because it's today's date. I would not call myself accredited at all, I should not be listened to for advice in any way. However I have a certain feeling that a buyout not a hostile takeover is in the works here, I would not be surprised at all if a offer has been made here....
Do your own DD!
I myself am an accredited investor, most of the time investing in not-yet-listed non-public companies. So the buyers are willing to wait a while and I'm sure there were some non-publicized understandings about what conditions have to be met before the non-public shares have their (probably) section 144 restriction removed. They clearly have confidence in CDXC.
I've been going thru weeks of rigamarole getting my restrictions lifted on another stock.
While that press release is great news, I was referencing the actual 8-k. Most specifically the last paragraph that states,
"The Shares are not registered under the Securities Act of 1933, as amended (the “Securities Act”), or any state securities laws. The Company has relied on the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and Rule 506 of Regulation D thereunder. In connection with the Purchaser’s execution of the Purchase Agreement, the Purchaser represented to the Company that it is an “accredited investor” as defined in Regulation D of the Securities Act and that the Shares purchased were acquired solely for its own account and for investment purposes and not with a view to the future sale or distribution."
* * $CDXC Video Chart 02-25-2021 * *
Link to Video - click here to watch the technical chart video
Thank you for refreshing my aging memory.
As summarized by MT newswire:
ChromaDex Shares Rally After COVID-19 Patients on Nutrient Recover Faster in Study
BY MT Newswires
— 3:12 PM ET 02/25/2021
03:12 PM EST, 02/25/2021 (MT Newswires) -- ChromaDex ( CDXC ) shares jumped more than 120% Thursday after a late-stage study showed that the addition of a nutritional protocol including nicotinamide riboside helped speed up the recovery of mild-to-moderate COVID-19 patients.
The nutritional addition reduced recovery time and improved liver health while lowering inflammation, according to the trial results published on medRxiv. ChromaDex ( CDXC
Loading... Loading...
) markets Tru Niagen, a cellular nutrient used to raise nicotinamide levels.
Separately, the company said it has raised $25 million after selling some 3.85 million shares to institutional investors at $6.50 each. It plans to use the proceeds to grow the Tru Niagen brand and for general corporate purposes.
Price: 22.55, Change: +12.81, Percent Change: +131.52
Notice the 8-k issued today? Give it a read and then decide what that means!
Yes he does going back to the old Safe Stitch days.
Whichever cause, my account balances are loving this.
VERY INTERESTING FOR SURE
This looks like a takeover attempt. The entire float has traded out of nowhere plus some.
For now let’s see
Good luck, Infinity. I'm a L-T holder. Cost basis 2-3.40 depending on the account. As you can tell, patience is my long suit; not trading. I assume you are attracted to the action.
Thanks. We shall see at some point. SP increase could also be a buy out.
Earnings must be really, really good and someone was waiting for the ph 3 covid trial as cover to “enter”!
Even more insane SP. Up 51 percent, with volume 30+X daily average.
Don't hold me to spelling, but Patrick Soong Shin?
Clearly, with the surge in SP and the volume after 1.5 hours of 10X the daily average over the last 90 days, someone thinks they know something. I believe Dr. Frost still owns a major number of shares.
Could be stellar earnings about to be reported. New international investor, this stock has been a sleeper with big fish like Zuckerberg (billionaire) Frost (billionaire), the other ((billionaire) Hong Kong investor( for get his name) soaking up the float ahead of earnings yet crickets.
Their science says it works and nobody cares.
Why the gap up today (Feb 25, 2021)?
RE: higher NAD+, this was just reported:
https://medicalxpress.com/news/2020-11-chronic-inflammation-reduction-nad.html
Higher NAD+ May Boost Immunity to Coronaviruses
From the Journal of Biological Chemistry:
"These data suggest that the antiviral activities of noncanonical PARP isozyme activities are limited by the availability of NAD, and that nutritional and pharmacological interventions to enhance NAD levels may boost innate immunity to coronaviruses."
Source: insert-text-here
Thanks I googled the same after posting.
Thanks I googled the same after posting.
Anybody know what a confidential treatment order is and why this company is using one? Long haul for shareholders and all they can produce is a CTO?
JUST IN: $CDXC ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%
Phase 2 study finds addition of nutritional protocol to standard of care reduces recovery time to 6.6 days from 9.3 in mild-to-moderate COVID-19 patients ChromaDex Corp. (NASDAQ:CDXC) today announced that results from the study “Combined metabolic cofactor supplementa...
In case you are interested CDXC - ChromaDex Announces Study Results Showing Nutritional Protocol Including Nicotinamide Riboside Plus Standard of Care Reduces Recovery Time in COVID-19 Patients by Nearly 30%
Absolutely amazing this message board has dried up as soon as the lawsuit is over. Price has also stabilized....hmmmm!
Oan my wife said she just saw a true niagen commercial on a network tv channel. Just a matter of time until this company gets bought out. Will Dr Frost and Nane Hasaio let this happen or will OPKO “absorb” Chromadex?
Tred
thanks for sharing. Good info good research.
Oral Argument Before CAFC on Elysium's Claim:
This morning Elysium got to argue its case on Claim 2 of the '086 Patent before the Court of Appeals for Federal Circuit. It didn't go great for Elysium.
https://www.right-of-assembly.org/post/oral-argument-before-the-cafc
First-of-its-Kind Clinical Study Initiated to Investigate Potential Benefits of Nicotinamide Riboside Combined with Exercise in Older Adults with Hypertension
Study expands on recently published preclinical data that showed improvements in aerobic performance following supplementation with ChromaDex’s novel form of vitamin B3
LOS ANGELES, Jan. 06, 2020 (GLOBE NEWSWIRE) -- ChromaDex Corp. (CDXC), the global scientific authority on nicotinamide adenine dinucleotide (NAD) and nicotinamide riboside (NR) science, announced today the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. This trial will assess the potential of NIAGEN® (NR) to enhance the effects of exercise therapy in older adults with hypertension. ChromaDex’s patent-protected NR is a unique form of vitamin B3 that is proven to safely increase NAD+ levels in the body. NAD+ declines as we age and is a critical coenzyme for cellular energy production and mitochondrial function, both important components of healthy human aging.
About one third of U.S. adults have hypertension, putting them at greater risk of cardiovascular disease, or even death. The benefits of exercise in helping to manage hypertension and enhance cardiovascular health are well documented. However, as individuals age, continuing a regular exercise routine can become more challenging due to age-associated physiological declines.
“This clinical trial will provide valuable information on the potential of NR supplementation to enhance the benefits of exercise in older populations with hypertension. Published data suggest NR may support cardiovascular health with further study, specifically through improvements in blood pressure (BP) and aortic stiffness. However, older hypertensive adults have yet to be explored in a clinical study,” said primary investigator Robert Mankowski, PhD, Department of Aging and Geriatric Research, the University of Florida.
This new randomized, double-blind study will evaluate the impact of NR supplementation combined with exercise in 74 hypertensive adults as measured by changes in arterial stiffness, blood pressure and walking performance. It was initiated as part of the ChromaDex External Research Program (CERP), where ChromaDex supplies its NR and placebo at no cost to research institutions worldwide.
“Through increases in NAD+, NR has the potential to improve cellular energy production, supplying individuals with the energy necessary to maintain a regular exercise routine,” said ChromaDex Chief Scientific Officer Dr. Matthew Roberts. “We look forward to enhancing our understanding of the use of NR as an adjuvant approach to exercise in promoting improvements in the cardiovascular health of aging adults.”
Niagen is the only commercially available nicotinamide riboside which has twice been successfully reviewed under FDA's new dietary ingredient (NDI) notification program and has also been successfully notified to the FDA as generally recognized as safe (GRAS).
* * $CDXC Video Chart 12-13-2019 * *
Link to Video - click here to watch the technical chart video
Followers
|
92
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3076
|
Created
|
10/28/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |